Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex321_6.htm |
| EX-31.2 - EX-31.2 - AVEO PHARMACEUTICALS, INC. | aveo-ex312_9.htm |
| EX-31.1 - EX-31.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex311_7.htm |
| EX-23.1 - EX-23.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex231_11.htm |
| EX-21.1 - EX-21.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex211_8.htm |
| EX-10.22 - EX-10.22 - AVEO PHARMACEUTICALS, INC. | aveo-ex1022_295.htm |
| EX-10.21 - EX-10.21 - AVEO PHARMACEUTICALS, INC. | aveo-ex1021_510.htm |
| 10-K - 10-K - AVEO PHARMACEUTICALS, INC. | aveo-10k_20171231.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of AVEO Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Keith Ehrlich, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to his knowledge on the date hereof:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 13, 2018
|
/s/ Matthew Dallas |
|
Matthew Dallas |
|
Chief Financial Officer (Principal Financial Officer) |